In this study, the binding of [3H] [3H]ryanodine is Ca2+-independent; it is slightly stimulated by NaCl, Mg2+, ATP and InsP3 but strongly inhibited by caffeine, diltiazem and sodium dantrolene. Thus the binding of ryanodine to endoplasmic reticulum membranes shares some of the characteristics of its binding to the sarcoplasmic reticulum but also differs from it in several important properties, such as its Ca2+-independence, its rapid association and dissociation, and its inhibition by caffeine. The structural similarities between the skeletal muscle and liver binding sites were further explored by employing in vitro DNA amplification techniques, using the known sequence of the skeletal muscle receptor as reference point. The data obtained with this method indicate that the liver does not process mRNA for the skeletal muscle ryanodine receptor.
INTRODUCTION
The endoplasmic reticulum (ER) in the liver plays an essential role in the regulation of cytosolic Ca2+ levels. In contrast with the relatively well-characterized mechanisms of Ca2+ uptake, the mechanism by which Ca2+ is released from the hepatic ER is poorly understood. Several mechanisms for Ca2+ release from the ER have been suggested, including mediation by InsP3 [1] or GTP [2, 3] , reversal of the Ca2+-ATPase reaction [4] and oxidation of thiol groups [5] . However, no specific Ca2+-efflux pathway or channel has been characterized.
In skeletal and cardiac muscle, the toxic alkaloid ryanodine has been successfully employed as an experimental tool to study Ca2+-release channels [6, 7] . At low concentrations (<1 ,UM) ryanodine was shown to stimulate the efflux of Ca2+ from the sarcoplasmic reticulum (SR), presumably by opening a Ca2+ channel [8, 9] , while at higher concentrations (> 100 /M) it inhibited Ca2+ release [6, 7] . Because of these findings it has been suggested that ryanodine is a Ca2+-release-channel-specific marker. The binding site for this marker was localized in the junctional SR membranes [10] .
The ryanodine receptor from skeletal and cardiac muscle SR has been purified and found to comprise a high-molecular-mass polypeptide [1 1-13] . Recently the molecular cloning of the cDNA encoding the ryanodine receptor of cardiac muscle SR has been reported [14] . The purified ryanodine receptor has been incorporated into planar lipid bilayers and found to form Ca2+-conducting pathways [12, 13, 15] . Structural analysis of the purified receptor suggested that it is morphologically identical to the junctional feet structures which connect the SR junction face membranes to the transverse tubule [11, 12] .
We have recently reported that ryanodine-binding sites are present in liver microsomes [16, 17 [. In the present study, ryanodine binding to the liver smooth ER is characterized and its differences from the skeletal muscle binding site are explored.
EXPERIMENTAL

Materials
Tris, EGTA, ATP, caffeine, aprotinin, DL-dithiothreitol (DTT), benzamidine and phenylmethane sulphonyl fluoride were obtained from Sigma.
[3H]Ryanodine was from Du Pont/New England Nuclear. Unlabelled ryanodine was obtained from Agricultural System International (Windgap, PA, U.S.A.).
Sodium dantrolene was obtained from Norwich Eaton Pharmaceuticals (Norwich, NY, U.S.A.), and was given to us by Dr. T. Nelson.
Membrane preparations
Liver microsomes were prepared from male Sprague-Dawley rats as described previously [18] , except that the liver was homogenized and the 105000 g pellet was resuspended in 0.25 Msucrose/lO mM-Mops (pH 7.1)/i mM-DTT containing the following proteinase inhibitors: 0.8 mM-benzamidine, 0.5 ,g of aprotinin/ml and 0.2 mM-phenylmethanesulphonyl fluoride. Microsomes were fractionated by sucrose-density-gradient centrifugation into rough ER (pellet), the membranes at the 1.3 M-sucrose phase (intermediate ER), and the 1.3/0.74 M-and 0.75/0.6 M-sucrose interfaces (smooth ER I and II respectively), as described previously [17, 18] . Briefly, the post-mitochondrial supernatant was sedimented at 105000 g for 1 h, and the pellet was resuspended in the above buffer to a final concentration of 15-20 mg of protein/ml. A sample (2 ml) of the suspension was carefully layered on top of 2 ml of 0.6 M-sucrose, 3 ml of 0.75 Msucrose and 5 ml of 1.3 M-sucrose (containing 15 mM-CsCl and 10 mM-Hepes, pH 7.2). After centrifugation for 2 h at 80000 g in a Beckman SW41 swinging bucket rotor, the membranes at the 0.6/0.75 M-sucrose and 0.75/1.3 M-sucrose interfaces and at the 1.3 M-sucrose phase were collected, diluted 3-fold with 100 mMKCl/20 mM-NaCI/5 mM-Hepes, pH 7.2, and centrifuged at 105 000 g for 1 h. The pellets obtained were resuspended in the sucrose/Mops buffer, quickly frozen in liquid N2 and stored at -70 'C. We added the 0.6 M-sucrose layer because the membranes at the 0.75/1.3 M-sucrose interface appeared as a fluffy double layer; the upper layer was a reddish colour and the lower layer was light brown. Some of the fluffy layer was separated on the 0.6/0.75 M-sucrose interface. In some experiments, the post-mitochondrial supernatant (5.5 ml per tube) was applied directly to the sucrose gradient. In this case the volume of the sucrose solutions applied in the gradient was half of that used above.
Hepatocytes, obtained by the collagenase liver perfusion method [19] , were homogenized in sucrose/Mops buffer by six up-and-down strokes in a Teflon homogenizer. The 3000 g pellet was homogenized again, the two post-mitochondrial supernatants were combined, and microsomes were obtained and fractionated as described above for the whole liver.
IHlRyanodine binding
Equilibrium binding to the different membrane fractions was determined by incubation of the membranes (1 mg/ml) for 10 min at 37 'C in 0. In the ultracentrifugation technique, the membranes were incubated with ryanodine, as described above, in a total volume of 150,1u in the centrifugation tubes of the Beckman Airfuge. After the incubation time the samples were centrifuged for 7 min at 130000 gmax.. The supernatant was removed immediately and carefully, the pellet was resuspended in 20 ,ul of 10 % SDS and the radioactivity was counted. The specific binding was determined as described above for the filtration method.
Amplification of ryanodine receptor sequences
Total RNA was isolated from rat quadriceps muscle and liver by homogenization in RNAsol (Biotech Laboratories, Houston, TX, U.S.A). Subsequent purification of the RNA was according to the manufacturer's recommendations. First-strand cDNAs were synthesized from 5 ,ug of total RNA using the cDNA cycle kit of Invitrogen (San Diego, CA, U.S.A.). One-tenth of the cDNA products were subjected to 40 cycles of polymerase chain reaction as described by Gibbs et al. [20] , using oligonucleotide primer pairs designed to be specific for the ryanodine receptor of skeletal muscle. A cycle consisted of 15 s at 94 'C, 15 s at 40 'C and 60 s at 72 'C. The final 72 'C incubation was extended to 8 min. The amplified products were characterized by electrophoresis through a 1 % agarose/1 % Nusieve gel (FMC BioProducts, Rockland, ME, U.S.A.).
Assays
Protein was determined according to [21] , with BSA as a standard. SDS/PAGE was performed as described by Laemmli [22] .
RESULTS
The distribution of ryanodine-binding sites in isolated microsomal fractions prepared from either intact liver or isolated hepatocytes is shown in Table 1 . This comparison was necessary in order to ascertain that binding sites present in the microsomes prepared from whole liver are not due to the small amounts of vascular smooth muscle that are also part of the organ. The results demonstrate that the [3H]ryanodine-binding capacities are similar in the two membrane preparations. The results also show that the smooth ER fraction is clearly enriched in [3H]ryanodine-binding sites.
Very low binding to the mitochondrial fraction was also detected and amounted to less than 10 % of that obtained with the smooth ER fraction (results not shown). This binding could be due to contamination with fragments of ER, as indicated by the presence of Ruthenium-Red-insensitive Ca2+ uptake and glucose 6-phosphatase activity in this fraction (results not shown). (Fig.  lb) . The apparent Kd, calculated from the slope, for the specific binding in four different membrane preparations was 10 + 2.5 M, and the Bmax was 400-600 fmol/mg of protein. The apparent concentration of the binding sites determined by the filtration method was a minimal value, since it did not take into account loss of microsomal protein through the filters and the loss of bound ryanodine during the filtration and washing time (about 20 s), which is expected because of the fast dissociation of ryanodine from its binding site (see Fig. 3 ). Therefore we also employed the centrifugation technique for measuring ryanodine binding (Figs. Ic and ld). As expected, the Kd obtained with this Dissociation experiments were performed by equilibrium binding of 20 nM-[3H]ryanodine with the membranes for 15 min at 37°C, and then dissociation of the labelled ryanodine was induced by the addition of excess unlabelled ryanodine and residual specific binding was determined after various periods of incubation at 37°C (Fig. 3) [6, 7, 10, 15, [23] [24] [25] [26] . Fig. 4 presents the effects of NaCl and pH on the binding of [3H]ryanodine to the liver smooth ER membranes. Fig. 4(a) shows that both total and specific binding were increased as the NaCl concentration Vol. 276 (Fig. 5) . Half-maximal inhibition was obtained at 25 ,M-dantrolene, a similar concentration to that reported to result in 50 % inhibition of ryanodine binding to L the CHAPS-solubilized ryanodine receptor of the SR [23] . We have shown previously [16] it strongly inhibited the binding of ryanodine to the liver smooth ig. 1. The inset represents a double-reciprocal ER (see also Fig. 6 and ref [16] ). [23] ). Similarly, dantrolene almost completely inhibited binding to the liver ER, but it only partially inhibited binding to the SR (Fig. 5) . i-fold at 0.5 M-NaCl). However, this stimuThe results presented above (Table 2 and Figs. 4-6) illustrate ,reat as that obtained for the binding of the significant differences between the ryanodine-binding sites muscle SR (over 10-fold) [11, 26] . present in the SR and those in liver ER membranes.
UFig. 4(b) show that the binding ofryanodine Rather than representing additional 'forms of ryanodineing optimal at pH 7.4 followed by a pro-binding protein, the differences in the kinetics and pharmaMis is in contrast with the SR, where the cological properties of ryanodine binding in liver and muscle might be explained by liver-specific modification of the muscle ryanodine receptor. To explore this possibility, we examined liver and skeletal muscle for the presence of the mRNA encoding the skeletal muscle ryanodine receptor using in vitro amplification techniques. Oligonucleotide primers were derived from regions of the rabbit receptor nucleotide sequence [25] , with minimal codon redundancy to maximize the likelihood that the primers would also recognize a sequence of rat origin ( results strongly suggest that the mRNA encoding the skeletal muscle form of the receptor is not expressed in liver and that the binding of ryanodine observed in liver cannot result from expression of a modified form of the skeletal muscle receptor.
DISCUSSION
The characterization of the hepatic microsomal ryanodinebinding process reveals striking differences between ryanodine binding in the liver and in skeletal muscle. These differences are evident and manifested in two ways: (1) in the characteristics of the binding itself; and (2) in the effects of pharmacological agents on the binding.
The presented data demonstrate that the binding sites originated from parenchymal-cell-derived microsomes and are not due to contamination with vascular smooth muscle SR. This is confirmed by the observation that microsomes and their subfractions prepared from isolated hepatocytes exhibited similar protein patterns and [3H]ryanodine binding to those ofmembrane fractios prepared from intact liver ( Table 1 ). The smooth ER fraction, which was obtained by a specific purification procedure on a Mg2+/sucrose gradient [17, 31] , showed an increase in [3H]ryanodine-binding sites compared with that of total microsomes. However, in these studies the contribution of ribosomal protein to the protein content of the fractions was not taken into consideration. If it was taken into consideration the differences between the rough and smooth microsomal fraction might be less pronounced.
The binding of ryanodine to the ER fractions shares some of the characteristics of binding to the SR, but also differs from it in several important ways. In the SR, ryanodine binds to highaffinity binding sites; recently, low-affinity binding sites have also been demonstrated [32] . In the liver, ryanodine also seems to bind to high-affinity sites, but low-affinity binding sites might be also present (results not shown). In contrast with that in skeletal muscle, the binding in liver is Ca2+-independent, it is not inhibited by either Mg2+ or Ruthenium Red, and it decreases at pH values above 7.5. According to the data presented here, the values for the total ryanodine binding sites (Bmax ) in the liver are lower than the reported values for skeletal muscle SR [6, 7, 23, 24] .
Binding affinities and Bmax values similar to those reported here for the liver were described in a recent study on a brain microsomal preparation [33] .
An additional important difference relates to the association/dissociation of ryanodine to and from its binding sites. In the liver at 37°C, the half-times of association and dissociation were 100-1000-fold lower than values reported for muscle (23.1 min and 14.4 h for association and dissociation respectively [24] ).
A comparison between the pharmacological profiles of the skeletal muscle SR and the liver ER ryanodine-binding sites also indicates significant differences. Ryanodine binding to the liver ER was strongly inhibited by caffeine, while at the same concentrations caffeine stimulated ryanodine binding to the SR (Table 2 , Fig. 6, [24] ). The muscle relaxant sodium dantrolene almost completely inhibited the binding of ryanodine to the liver ER, but it only partially inhibited binding to SR membranes. The inhibition of ryanodine binding by caffeine and dantrolene (Figs. 5 and 6) may suggest that these compounds bind to the same ryanodine-binding protein or to a closely associated polypeptide(s). The Ca2+-channel antagonist diltiazem also strongly inhibited the binding of ryanodine to the hepatic ER, but only slightly affected the binding to SR membranes (see Table 2 and [23] ). It should be mentioned, however, that diltiazem was found to be as effective as dantrolene in preventing the abnormal contraction of skeletal muscle induced by halothane and caffeine in malignant hyperpyrexia-susceptible muscle (34, 35) . Also, as mentioned above, Ruthenium Red has no significant effect on binding of ryanodine to the hepatic ER, but it is a potent inhibitor of ryanodine binding to the SR [6, 23] .
Further structural differences are indicated by the observation that, by using different antibodies, and in contrast with a previous report [16] , no interaction was found between the hepatic microsomal fractions and antibodies raised against the purified skeletal muscle ryanodine receptor in two laboratories (J. R. Dedman & A. Lai, personal communication).
The most probable explanation for the differences in the binding of ryanodine to liver and skeletal muscle is the existence of multiple proteins capable of binding ryanodine. Indeed, the existence of multiple forms of the ryanodine receptor has been confirmed by the recent isolation of the cDNA encoding the cardiac form [14] . Binding studies alone, however, cannot exclude the possibility that the observed differences between liver and skeletal muscle might result from the expression of a modified form of the skeletal muscle receptor in liver. This seems unlikely, as oligonucleotide primer pairs directed to two different sites on the skeletal muscle sequence failed to amplify the mRNA encoding the muscle form of the receptor in liver (Fig. 7) . The observed absence of the muscle receptor mRNA in liver on using amplification techniques is consistent with recent studies in which the tissue specificity of the skeletal muscle and cardiac forms of the receptor were examined. Otsu et al. [14] found that neither the skeletal muscle cDNA nor the cardiac cDNA probes hybridized to any mRNA species in liver. These findings raise the possibility that the ryanodine-binding protein in the liver represents an additional form of the ryanodine receptor.
